Need Assistance?

US & Canada:
+
UK: +

FAQs

Resources

Our Highlights

GMP Grade Efficient workshop for GMP production.
Optimal Prices Buying products on this site guarantees the best price!
Commercial Batches Independent GMP manufacturing suites that handle commercial batches
Prompt Delivery Warehouses in multiple cities to ensure timely delivery
Flexible Quantity Quantities available from milligrams to ton

Application Area

Clavanin-B

* Please kindly note that our products are not to be used for therapeutic purposes and cannot be sold to patients.

Clavanin B is an alpha-helical antimicrobial peptide isolated from Styela clava.

Category

Functional Peptides

Catalog number

BAT-013428

Molecular Formula

C131H184N36O27

Molecular Weight

2695.08

Specification
Reference Reading

IUPAC Name

(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3S)-2-[[(2S,3S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-amino-3-methylbutanoyl]amino]-3-phenylpropanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylpentanoyl]amino]-3-methylpentanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-3-methylbutanoyl]amino]acetyl]amino]-4-oxobutanoyl]amino]-3-phenylpropanoyl]amino]-3-methylbutanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-3-methylbutanoyl]amino]-3-phenylpropanoic acid

Sequence

VFQFLGRIIHHVGNFVHGFSHVF

InChI

InChI=1S/C131H184N36O27/c1-15-75(13)109(167-129(192)110(76(14)16-2)166-114(177)86(43-32-46-141-131(135)136)149-102(171)62-142-111(174)88(47-70(3)4)153-117(180)90(49-78-35-24-18-25-36-78)154-113(176)87(44-45-100(132)169)152-116(179)91(50-79-37-26-19-27-38-79)158-124(187)105(134)71(5)6)128(191)160-94(54-83-59-138-67-146-83)118(181)156-95(55-84-60-139-68-147-84)121(184)163-106(72(7)8)125(188)144-64-104(173)151-97(57-101(133)170)119(182)155-92(51-80-39-28-20-29-40-80)120(183)164-107(73(9)10)126(189)159-93(53-82-58-137-66-145-82)112(175)143-63-103(172)150-89(48-77-33-22-17-23-34-77)115(178)162-99(65-168)123(186)157-96(56-85-61-140-69-148-85)122(185)165-108(74(11)12)127(190)161-98(130(193)194)52-81-41-30-21-31-42-81/h17-31,33-42,58-61,66-76,86-99,105-110,168H,15-16,32,43-57,62-65,134H2,1-14H3,(H2,132,169)(H2,133,170)(H,137,145)(H,138,146)(H,139,147)(H,140,148)(H,142,174)(H,143,175)(H,144,188)(H,149,171)(H,150,172)(H,151,173)(H,152,179)(H,153,180)(H,154,176)(H,155,182)(H,156,181)(H,157,186)(H,158,187)(H,159,189)(H,160,191)(H,161,190)(H,162,178)(H,163,184)(H,164,183)(H,165,185)(H,166,177)(H,167,192)(H,193,194)(H4,135,136,141)/t75-,76-,86-,87-,88-,89-,90-,91-,92-,93-,94-,95-,96-,97-,98-,99-,105-,106-,107-,108-,109-,110-/m0/s1

InChI Key

KENGXPKQZMFVCK-PWWQNGLPSA-N

Canonical SMILES

CCC(C)C(C(=O)NC(C(C)CC)C(=O)NC(CC1=CN=CN1)C(=O)NC(CC2=CN=CN2)C(=O)NC(C(C)C)C(=O)NCC(=O)NC(CC(=O)N)C(=O)NC(CC3=CC=CC=C3)C(=O)NC(C(C)C)C(=O)NC(CC4=CN=CN4)C(=O)NCC(=O)NC(CC5=CC=CC=C5)C(=O)NC(CO)C(=O)NC(CC6=CN=CN6)C(=O)NC(C(C)C)C(=O)NC(CC7=CC=CC=C7)C(=O)O)NC(=O)C(CCCNC(=N)N)NC(=O)CNC(=O)C(CC(C)C)NC(=O)C(CC8=CC=CC=C8)NC(=O)C(CCC(=O)N)NC(=O)C(CC9=CC=CC=C9)NC(=O)C(C(C)C)N

1. Outcomes for Ladd's procedure: Does approach matter?

Rebecca A Saberi, Gareth P Gilna, Blaire V Slavin, Alessia C Cioci, Eva M Urrechaga, Joshua P Parreco, Eduardo A Perez, Juan E Sola, Chad M Thorson J Pediatr Surg. 2022 Jan;57(1):141-146. doi: 10.1016/j.jpedsurg.2021.09.016. Epub 2021 Sep 20.

Background: Laparoscopic Ladd's procedure has been proven safe and effective for the treatment of malrotation. However, the nationwide utilization and outcomes of elective Ladd's procedure are largely unknown. Methods: The Nationwide Readmissions Database from 2010 to 2014 was used to identify patients 0-18 years (excluding newborns) with malrotation who underwent elective Ladd's procedure. Demographics, hospital factors, and outcomes were compared by approach (laparoscopic vs. open) using standard statistical tests and propensity score (PS) matched analysis. Results were weighted for national estimates. Results: 1343 patients (44% male) underwent elective Ladd's procedure via laparoscopic (22%) or open (78%) approach. Laparoscopic approach was more common in large hospitals (26% vs. 16%), patients >13 years (30% vs. 20%), and those with higher income (29% vs. 16%), all p < 0.001. Following PS matching, compared to the laparoscopic approach, open Ladd's was associated with index hospital length of stay > 7 days (20% vs. 8%), more post-operative gastrointestinal dysfunction (12% vs. < 1%), and more nausea, vomiting, and/or diarrhea (16% vs. 6%), all p < 0.001. The overall readmission rates within 30 days and the year of index operation were 8% and 15%, respectively. In the matched cohort, those undergoing laparoscopic Ladd's were less likely to be readmitted than those with the open approach (7% vs. 16%, p < 0.001) and experienced less gastrointestinal issues on readmission (5% vs. 15%, p = 0.002). There were similar rates of post-operative small bowel obstruction (< 3% vs. < 3%, p = 0.840) and volvulus (0% vs. < 1%, p = 0.136). Redo Ladd's procedure was performed in less than 4% of readmissions and all occurred within 5 days of initial hospital discharge. Conclusion: The majority of Ladd's procedures in the U.S. are being performed open, despite comparable outcomes following a laparoscopic approach. Readmission rates are similar with either approach, and the rate of redo Ladd's procedure is lower than previously reported. Level of evidence: Level III.